• 1
    Smith RA, Saslow D, Sawyer KA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 2003; 53:141169.
  • 2
    Heywang-Kobrunner SH, Bick U, Bradley WG, Jr, et al. International investigation of breast MRI: results of a multicentre study (11 sites) concerning diagnostic parameters for contrast-enhanced MRI based on 519 histopathologically correlated lesions. Eur Radiol 2001; 11:531546.
  • 3
    Gilles R, Guinebretiere JM, Toussaint C, et al. Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 1994; 191:633638.
  • 4
    Harms SE, Flamig DP, Hesley KL, et al. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 1993; 187:493501.
  • 5
    Fischer U, von Heyden D, Vosshenrich R, et al. Signal characteristics of malignant and benign lesions in dynamic 2D-MRT of the breast (in German). Rofo 1993; 158:287292.
  • 6
    Boetes C, Barentsz JO, Mus RD, et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology 1994; 193:777781.
  • 7
    Liu PF, Debatin JF, Caduff RF, et al. Improved diagnostic accuracy in dynamic contrast enhanced MRI of the breast by combined quantitative and qualitative analysis. Br J Radiol 1998; 71:501509.
  • 8
    Orel SG, Schnall MD. MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology 2001; 220:1330.
  • 9
    Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351:427437.
  • 10
    Kuhl CK, Schrading S, Leutner CC, et al. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 2005; 23:84698476.
  • 11
    Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365:17691778.
  • 12
    Lehman CD, Blume JD, Weatherall P, et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 2005; 103:18981905.
  • 13
    Sardanelli F. Breast MR imaging in women at high risk of breast cancer. Is something changing in early breast cancer detection? Eur Radiol. In press.
  • 14
    Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292:13171325.
  • 15
    U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005; 143:355361.
  • 16
    Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 1994; 73:643651.
  • 17
    Palomaki GE, McClain MR, Steinort K, et al. Screen-positive rates and agreement among six family history screening protocols for breast/ovarian cancer in a population-based cohort of 21- to 55-year-old women. Genet Med 2006; 8:161168.
  • 18
    Parmigiani G, Berry D, Aguilar O. Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998; 62:145158.
  • 19
    Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:6671.
  • 20
    Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265:20882090.
  • 21
    Amir E, Evans DG, Shenton A, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. J Med Genet 2003; 40:807814.
  • 22
    Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989; 81:18791886.
  • 23
    Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 2004; 23:11111130.
  • 24
    Domchek SM, Eisen A, Calzone K, et al. Application of breast cancer risk prediction models in clinical practice. J Clin Oncol 2003; 21:593601.
  • 25
    McTiernan A, Kuniyuki A, Yasui Y, et al. Comparisons of two breast cancer risk estimates in women with a family history of breast cancer. Cancer Epidemiol Biomarkers Prev 2001; 10:333338.
  • 26
    Berry DA, Parmigiani G, Sanchez J, et al. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997; 89:227238.
  • 27
    Antoniou AC, Pharoah PP, Smith P, Easton DF. The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 2004; 91:15801590.
  • 28
    Petrucelli N, Daly MB, Culver JOB, et al. BRCA1 and BRCA2 Hereditary Breast/Ovarian Cancer. Gene Reviews. Available at: Accessed December 28, 2006.
  • 29
    Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 1996; 14:185187.
  • 30
    Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336:14011408.
  • 31
    Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72:11171130.
  • 32
    American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003; 21:23972406.
  • 33
    Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005; 23:276292.
  • 34
    Schneider KA, DiGianni LM, Patenaude AF, et al. Accuracy of cancer family histories: comparison of two breast cancer syndromes. Genet Test 2004; 8:222228.
  • 35
    Zbuk KM, Stein JL, Eng C. PTEN Hamartoma Tumor Syndrome (PHTS). Gene Reviews. Available at: Accessed October 17, 2006.
  • 36
    Aisenberg AC, Finkelstein DM, Doppke KP, et al. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 1997; 79:12031210.
  • 37
    Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996; 334:745751.
  • 38
    Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993; 85:2531.
  • 39
    Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000; 18:498509.
  • 40
    Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005; 97:14281437.
  • 41
    Wahner-Roedler DL, Nelson DF, Croghan IT, et al. Risk of breast cancer and breast cancer characteristics in women treated with supradiaphragmatic radiation for Hodgkin lymphoma: Mayo Clinic exper ience. Mayo Clin Proc 2003; 78:708715.
  • 42
    van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003; 95:971980.
  • 43
    Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003; 21:43864394.
  • 44
    Tinger A, Wasserman TH, Klein EE, et al. The incidence of breast cancer following mantle field radiation therapy as a function of dose and technique. Int J Radiat Oncol Biol Phys 1997; 37:865870.
  • 45
    Arpino G, Laucirica R, Elledge RM. Premalignant and in situ breast disease: biology and clinical implications. Ann Intern Med 2005; 143:446457.
  • 46
    Fisher ER, Land SR, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer 2004; 100:238244.
  • 47
    Li CI, Malone KE, Saltzman BS, Daling JR. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 19882001. Cancer 2006; 106:21042112.
  • 48
    Boyd NF, Lockwood GA, Martin LJ, et al. Mammographic densities and breast cancer risk. Breast Dis 1998; 10:113126.
  • 49
    Oza AM, Boyd NF. Mammographic parenchymal patterns: a marker of breast cancer risk. Epidemiol Rev 1993; 15:196208.
  • 50
    Saftlas AF, Szklo M. Mammographic parenchymal patterns and breast cancer risk. Epidemiol Rev 1987; 9:146174.
  • 51
    Warner E, Lockwood G, Tritchler D, Boyd NF. The risk of breast cancer associated with mammographic parenchymal patterns: a meta-analysis of the published literature to examine the effect of method of classification. Cancer Detect Prev 1992; 16:6772.
  • 52
    Barlow WE, White E, Ballard-Barbash R, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer Inst 2006; 98:12041214.
  • 53
    Boyd NF, Byng JW, Jong RA, et al. Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 1995; 87:670675.
  • 54
    Brisson J, Merletti F, Sadowsky NL, et al. Mammographic features of the breast and breast cancer risk. Am J Epidemiol 1982; 115:428437.
  • 55
    Byrne C, Schairer C, Wolfe J, et al. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst 1995; 87:16221629.
  • 56
    Vacek PM, Geller BM. A prospective study of breast cancer risk using routine mammographic breast density measurements. Cancer Epidemiol Biomarkers Prev 2004; 13:715722.
  • 57
    Ursin G, Ma H, Wu AH, et al. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomarkers Prev 2003; 12:332338.
  • 58
    Ursin G, Hovanessian-Larsen L, Parisky YR, et al. Greatly increased occurrence of breast cancers in areas of mammographically dense tissue. Breast Cancer Res 2005; 7:R605R608.
  • 59
    Fowble B, Hanlon A, Freedman G, et al. Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk. Int J Radiat Oncol Biol Phys 2001; 51:679690.
  • 60
    Warren RM, Pointon L, Thompson D, et al. Reading protocol for dynamic contrast-enhanced MR images of the breast: sensitivity and specificity analysis. Radiology 2005; 236:779788.
  • 61
    Port ER, Park A, Borgen PI, et al. Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia. Ann Surg Oncol 2007; Jan 7 [E pub ahead of print].
  • 62
    Warner E, Causer PA. MRI surveillance for hereditary breast-cancer risk. Lancet 2005; 365:17471749.
  • 63
    Kuhl CK, Schmutzler RK, Leutner CC, et al. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: preliminary results. Radiology 2000; 215:267279.
  • 64
    Anderson J, Walker LG, Leach MO. Magnetic resonance imaging: an acceptable way of screening women with a family history of breast cancer. Breast Cancer Res Treat 2004; 88(suppl):S188.
  • 65
    van Dooren S, Seynaeve C, Rijnsburger AJ, et al. Exploring the course of psychological distress around two successive control visits in women at hereditary risk of breast cancer. Eur J Cancer 2005; 41:14161425.
  • 66
    Warner E. Intensive radiologic surveillance: a focus on the psychological issues. Ann Oncol 2004; 15(suppl):I43I47.
  • 67
    Hill K, Warner E. Are clinical breast examination and breast self-examination a source of stress or relief for BRCA mutation carriers? In: Programs and abstracts of the 29th Annual San Antonio Breast Cancer Symposium; December 14–17, 2006; San Antonio, Texas. Abstract 4036.
  • 68
    Plevritis SK, Kurian AW, Sigal BM, et al. Costeffectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA 2006; 295:23742384.
  • 69
    Griebsch I, Brown J, Boggis C, et al. Costeffectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer. Br J Cancer 2006; 95:801810.
  • 70
    National Institute for Clinical Excellence (NICE), National Collaborating Centre for Primary Care. Familial breast cancerThe classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. Partial update. Draft for consultation. May 2006. Available at: Accessed December 29, 2006.
  • 71
    Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 2004; 233:830849.
  • 72
    Bluemke DA, Gatsonis CA, Chen MH, et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA 2004; 292:27352742.
  • 73
    Echevarria JJ, Martin M, Saiz A, et al. Overall breast density in MR mammography: diagnostic and therapeutic implications in breast cancer. J Comput Assist Tomogr 2006; 30:140147.
  • 74
    Sardanelli F, Giuseppetti GM, Panizza P, et al. Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in fatty and dense breasts using the whole-breast pathologic examination as a gold standard. AJR Am J Roentgenol 2004; 183:11491157.
  • 75
    Morris EA, Liberman L, Ballon DJ, et al. MRI of occult breast carcinoma in a high-risk population. AJR Am J Roentgenol 2003; 181:619626.
  • 76
    Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56:265271.
  • 77
    Burke W, Daly M, Garber J, et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 1997; 277:9971003.
  • 78
    Tilanus-Linthorst MM, Kriege M, Boetes C, et al. Hereditary breast cancer growth rates and its impact on screening policy. Eur J Cancer 2005; 41:16101617.
  • 79
    National Cancer Institute, Division of Cancer Control and Population Sciences, Applied Research Program. Breast Cancer Surveillance Consortium: Evaluating Screening Performance in Practice. NIH Publication No. 045490. Bethesda, MD: National Cancer Institute, National Institutes of Health, U. S. Department of Health and Human Services; 2004. Available at: Accessed December 29, 2006.